Chronic inflammatory demyelinating polyneuropathy (CIDP): therapeutic updates, best practices, and emerging therapies
Cost: FreeView Offer chevron_right
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.
After viewing Chronic inflammatory demyelinating polyneuropathy (CIDP), you will be able to:
• Describe the pathophysiology of CIDP such that it might inform treatment mechanisms
• Identify the currently available and emerging pharmacotherapeutic treatments for management of CIDP and apply them to patient cases using evidence-based medicine
• Modify an existing treatment plan for a specific patient with CIDP to optimize safety and efficacy following non-response to therapy
• Describe non-pharmacological options to manage CIDP
Healthcare professionals specializing in: neurology, internal medicine; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with CIDP.